You are here: Industry Insights > Boehringer Ingelheim

News List

Boehringer Ingelheim break ground on $217 million Fremont facility pharmafile
August 02, 2017
Boehringer Ingelheim announced that it had broken ground on its planned $217 million upgrade and expansion of its existing Fermont manufacturing facility.
Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight th lilly
August 01, 2017
Boehringer Ingelheim and Eli Lilly and Company announced that the companies will support an American College of Cardiology (ACC) program focused on driving quality improvement in cardiology and...
Boehringer Ingelheim breaks ground on $217 million expansion of Fremont, California manufacturing fa cphi-online
July 25, 2017
Expansion will triple capacity, add nearly 300 new jobs.
Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab bio worldpharmanews
June 16, 2017
Boehringer Ingelheim has announced results from the pivotal Phase III VOLTAIRE®-RA(1) study.
Boehringer Ingelheim builds Digital Lab "BI X" with focus on innovative digital solutions in healthc worldpharmanews
June 13, 2017
With the founding of BI X as independent subsidiary Boehringer Ingelheim will focus on breakthrough innovative digital solutions in healthcare from idea to pilot.
Boehringer Ingelheim inaugurates biopharmaceutical manufacturing facility in China cphi-online
May 25, 2017
It is the first and only biopharmaceutical manufacturing site established by a multinational active pharmaceutical company in China.
Boehringer opens biopharmaceutical manufacturing facility in China pharmaceutical-technology
May 18, 2017
Germany’s Boehringer Ingelheim has officially opened its commercial production site for biopharmaceuticals in Zhang Jiang Hi-tech Park in Shanghai, China.
Boehringer Ingelheim inaugurates world-class biopharmaceutical manufacturing facility in China worldpharmanews
May 17, 2017
Boehringer Ingelheim inaugurated its commercial production site for biopharmaceuticals in Zhang Jiang Hi-tech Park of Shanghai (China).
Boehringer Ingelheim posts financial year 2016 report financialexpress
April 07, 2017
Net sales rise to around 15.9 billion euros, operating income improves to around 2.9 billion euros
FDA Grants Orphan Drug Designation to Boehringer Ingelheim's Investigational Anti-CD33 Monoclonal An americanpharmaceuticalreview
March 13, 2017
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its anti-CD33 monoclonal antibody BI 836858 for the treatment of myelodysplastic syndromes (MDS).

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page